These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 27123978)
1. Design, Synthesis, and Biological Activity of Isosyringolin A. Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978 [TBL] [Abstract][Full Text] [Related]
2. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells. Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship study of syringolin A as a potential anticancer agent. Chiba T; Matsuda A; Ichikawa S Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of a Structurally Simplified Syringolin A Analogues. Chiba T; Kitahata S; Matsuda A; Ichikawa S Chem Pharm Bull (Tokyo); 2016; 64(7):811-6. PubMed ID: 27373636 [TBL] [Abstract][Full Text] [Related]
5. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells. Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design of human immuno- and constitutive proteasomes inhibitors. Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors. Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma. Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors. Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids. Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors. Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021 [TBL] [Abstract][Full Text] [Related]
12. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors. Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361 [TBL] [Abstract][Full Text] [Related]
13. Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor. Trivella DB; Pereira AR; Stein ML; Kasai Y; Byrum T; Valeriote FA; Tantillo DJ; Groll M; Gerwick WH; Moore BS Chem Biol; 2014 Jun; 21(6):782-91. PubMed ID: 24930969 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives. Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524 [TBL] [Abstract][Full Text] [Related]
15. Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells. Obara T; Kawano N; Tatsumi K; Katsuyama A; Nakajima K; Ogawa M; Ichikawa S Bioorg Med Chem; 2024 Jun; 108():117773. PubMed ID: 38850999 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer. Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome. Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors. Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]